Who said What in Business, Finance and Innovations of Biotech and Pharmaceutical Industries?


In this passing month we brought to you many interesting and innovative research & development news, many game changing collaborations and tie ups and quenched you with the insights of the most hottest technologies and innovations in the pharmaceutical, biotechnology and chemical industries. Every news was embellished with a promise that researchers and scientists made regarding their innovation and a hope that the collaborators filled us with to take R&D to a level higher and benefit the human race,  so let us check out who said what….. 

Quote 1.

FDA’s approval of Defitelio underscores the importance of Defitelio to children and adults as the first and only proven treatment for this rare and often deadly complication of stem-cell transplantation. Defitelio is a clinically significant therapeutic advance because it is a potentially curative intervention for patients with VOD, which may save lives with a single course of therapy. Before today, patients in the U.S. had no approved options”. – Who said it? Answer is here

 Quote 2.

The ability to expand robotic precision to treat my peripheral disease patients is an important addition; I am looking forward to continued work with Corindus to optimize robotic therapy for peripheral procedures”. – Who said it? Answer is here

Quote 3.

The Insulin Glargine approval in the highly regulated market like Japan, marks a huge credibility milestone for Biocon. We see this as a significant achievement in our journey of making global impact in diabetes management through our affordable biosimilar insulins. We hope to enable the Japanese government to bring down its healthcare expenditure on diabetes with the use of this cost effective, high quality biosimilar Insulin Glargine”.- Who said it? Answer is here

Quote 4.

Through this research, we discovered Gleevec, which is used in leukemia medications, can inhibit the phosphorylation of PPARγ”.- Who said it? Answer is here

Quote 5.

XP23829 complements our internal development efforts, which have primarily focused on the mild-to-moderate psoriasis segment to date. In other markets, fumarates have been used as first line choices of treatment prior to initiation of biologic therapies in patients with moderate-to-severe psoriasis. We intend to initiate the registration program for XP23829 as soon as feasible so that we can accelerate the availability of this important treatment choice for moderate-to-severe psoriasis patients in the U.S. market”.- Who said it? Answer is here

Quote 6.

By combining UC Berkeley’s leading research and academic resources with innovative technology platforms, such as those developed by Aduro, we are confident that this initiative will lead to an improved understanding of, and potential treatments for, some of the most devastating diseases”.- Who said it? Answer is here

Quote 7.

perhaps the most exciting breakthrough in cancer diagnostics”.- Who said it? Answer is here

Quote 8.

This new agreement reflects our shared commitment to being leaders in ophthalmology and to now pursue the goal of improving anatomical and visual outcomes for patients with retinal eye diseases”.- Who said it? Answer is here

Quote 9.

Our non-invasive treatments are well suited to bridge the enormous gap between medical management and surgical interventions for this very large group of patients”.- Who said it? Answer is here

Quote 10.

“By pursuing a treatment approach which may address disease progression earlier, we hope to transform the lives of patients with RA and other autoimmune diseases”.- Who said it? Answer is here

Quote 11.

“As preparedness is a cornerstone of any bioterrorism response, we are pleased to see continued efforts to develop treatments for anthrax”.- Who said it? Answer is here

Quote 12.

“These positive results from BRIDGE add to our growing body of phase III data demonstrating romosozumab’s potential to build bone strength and to decrease fracture risk and thus help fill an unmet need for patients with osteoporosis.”- Who said it? Answer is here

Quote 13.

“The FDA’s designation of NI-0501 as a Breakthrough Therapy recognizes the potential of NI-0501 to address an important unmet medical need in a disease with still high mortality, and for which there are no approved treatments”.- Who said it? Answer is here

Quote 14.

“We are proud that, based on our comprehensive development program, physicians can now consider twice weekly prophylactic treatment with Kovaltry among the treatment options”.Who said it? Answer is here

Quote 15.

“We’re thrilled to announce FDA 510(k) clearance to market for MoMe Kardia, which supports our mission to create superior patient monitoring solutions for arrhythmia detection and chronic disease management”.- Who said it? Answer is here

Quote 16.

“We hope this partnership will help deliver essential therapies against currently intractable disease targets, and help patients who otherwise have been unable to receive treatments outside of the inpatient setting. This initiative will allow our teams to combine their wealth of knowledge in drug discovery and further strengthens Sanofi’s commitment to open innovation”.Who said it? Answer is here

Quote 17.

“We believe Blueprint Medicines’ proprietary drug discovery platform and expertise in immuno kinases, combined with our proven ability to move quickly through drug discovery, is a perfect complement to Roche’s expertise with cancer immunotherapy biology and in developing and commercializing innovative therapies”. –Who said it? Answer is here

Quote 18.

“You punch a little hole, and (the surgical robot) uses a ‘smart’ head with a camera to find its way to the viscera, then a tool grafts the electrode to the nerve“.-Who said it? Answer is here

Quote 19.

We’ve seen how the commercialization of genome sequencing has created incredible opportunities to improve human health, and now the epigenome holds similar potential. Cambridge Epigenetix is one of the few teams on the planet with the skills and experience to break new ground here, and we look forward to supporting them on that journey”.Who said it? Answer is here

Quote 20.

The results of this Epidiolex pivotal trial are important and exciting as they represent the first placebo-controlled evidence to support the safety and efficacy of pharmaceutical cannabidiol in children with Dravet syndrome, one of the most severe and difficult-to-treat types of epilepsy”.Who said it? Answer is here

Quote 21.

These findings deepen understanding of the mechanisms that our immune system uses to protect against cancer and potentially against other serious diseases caused by pathogenic viral proteins“.Who said it? Answer is here

Quote 22.

“We hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months”.-Who said it? Answer is here

Quote 23.

“Receiving the orphan drug designation request for spinocerebellar ataxia supports our global development strategy and goal of providing improved therapies for patients suffering from neurologic disorders with unmet need”.-Who said it? Answer is here

Quote 24.

“This study represents the first vaccine study to test the effectiveness of a P. vivax vaccine candidate in humans using controlled human malaria infection“.-Who said it? Answer is here

Quote 25.

“Through this collaboration, we hope to advance our understanding of how FAK inhibition may complement our development program for avelumab, with the ultimate goal of potentially achieving better outcomes for women with ovarian cancer”.-Who said it? Answer is here

Quote 26.

“The generation of molecular scalpels, such as the Brec1 recombinase, will change medical practice. Not only HIV patients will likely benefit from this development, but also many other patients with genetically caused diseases. We are about to witness the beginning of the genome surgery era”.-Who said it? Answer is here

P.S. Wasn’t this too much too read? So we have decided to present this summary every week (preferably Monday)

Leave a reply

Your email address will not be published. Required fields are marked *